Literature DB >> 26653562

Prognostic value of regulator of G-protein signaling 6 in colorectal cancer.

Yang Luo1, Shao-Lan Qin1, Min-Hao Yu1, Yi-Fei Mu1, Zheng-Shi Wang1, Ming Zhong2.   

Abstract

Reprogrammed metabolism is a hallmark of cancer cells. Regulator of G-protein signaling 6 (RGS6), which is frequently down-regulated in multiple human malignancies, has been demonstrated to play a critical function in energy metabolism, cell apoptosis and tumorigenesis. However, limited knowledge is known about the expression pattern and prognostic value of RGS6 in colorectal cancer (CRC). In this study, we first observed that RGS6 mRNA and protein is commonly downregulated in 32 paired CRC tissues compared with their normal counterparts. Furthermore, by a large scale of immunohistochemical analysis in a tissue microarray containing 310 cases of CRC specimens, we demonstrated that the protein expression of RGS6 expression is downregulated in 40.97% (127/310) samples and detected that decreasing RGS6 expression is closely correlated with enhanced tumor size, CEA level, T classification, TNM stage, and easier lymphatic and distant metastasis. Meanwhile, Kaplan-Meier survival analysis showed that CRC patients with a lower RGS6 expression have a poorer clinical outcome than those with a higher RGS6 expression. Multivariate Cox regression analysis revealed that RGS6, lymphatic metastasis and distant metastasis are the independent prognostic factors for overall survival rate of CRC patients. Taken together, our studies reveal the prognostic value of RGS6 in CRC and support that RGS6 may act as a molecular target for CRC treatment.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Metastasis; Prognosis; RGS6

Mesh:

Substances:

Year:  2015        PMID: 26653562     DOI: 10.1016/j.biopha.2015.10.012

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  High expression of WWP1 predicts poor prognosis and associates with tumor progression in human colorectal cancer.

Authors:  Jian-Jun Chen; Wei Zhang
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

2.  RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation.

Authors:  Jianqi Yang; Lance T Platt; Biswanath Maity; Katelin E Ahlers; Zili Luo; Zhibo Lin; Bandana Chakravarti; Stella-Rita Ibeawuchi; Ryan W Askeland; Jolanta Bondaruk; Bogdan A Czerniak; Rory A Fisher
Journal:  Oncotarget       Date:  2016-10-25

3.  Cancer astrocytes have a more conserved molecular status in long recurrence free survival (RFS) IDH1 wild-type glioblastoma patients: new emerging cancer players.

Authors:  Sara Franceschi; Francesca Lessi; Paolo Aretini; Valerio Ortenzi; Cristian Scatena; Michele Menicagli; Marco La Ferla; Prospero Civita; Katia Zavaglia; Claudia Scopelliti; Alessandro Apollo; Francesco Giovanni Carbone; Riccardo Vannozzi; Generoso Bevilacqua; Francesco Pasqualetti; Antonio Giuseppe Naccarato; Chiara Maria Mazzanti
Journal:  Oncotarget       Date:  2018-05-08

4.  Protein Profiling of RGS6, a Pleiotropic Gene Implicated in Numerous Neuropsychiatric Disorders, Reveals Multi-Isoformic Expression and a Novel Brain-Specific Isoform.

Authors:  K E Ahlers-Dannen; J Yang; M M Spicer; B Maity; A Stewart; J G Koland; R A Fisher
Journal:  eNeuro       Date:  2022-01-18

5.  RGS6 suppresses TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancers via a novel mechanism dependent on its interaction with SMAD4.

Authors:  Zhao Wang; Jun Chen; Shengjie Wang; Zelong Sun; Zhe Lei; Hong-Tao Zhang; Jie Huang
Journal:  Cell Death Dis       Date:  2022-07-28       Impact factor: 9.685

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.